With the coronavirus outbreak dominating global news over several months, the pharmaceutical industry has come under spotlight to increase the production capabilities in vaccines and other effective treatment options. Stakeholders in the pharmaceutical contract sales outsourcing (CSO) market are taking advantage of these developments to meet the demand of consumers and healthcare facilities. The growing awareness about enhancing the immune system is another key driver generating revenue opportunities for stakeholders in the pharmaceutical contract sales outsourcing (CSO) market during the ongoing pandemic.
In order to adapt to changing market sentiments, an increasing number of pharmaceutical companies is looking to outsource contract manufacturing organizations (CMOs). Thus, CSO plays an important role in generating prospects, nurturing leads, and moving clients through the sales pipeline. Health-related product sales have been soaring as the virus started to take hold.
The pharmaceutical contract sales outsourcing (CSO) market is projected to expand at a favorable CAGR of ~7% during the assessment period. However, pharmaceutical firms are still warming up to the idea of outsourcing. Established companies who are witnessing an increased demand for products are opting for outsourcing to meet the needs of end users.
Pharmaceutical and biotech companies are presently grappling with complex drug trials, highly regulated promotional programs, and complex supply chains. Hence, companies in the pharmaceutical contract sales outsourcing (CSO) market are stepping in to provide unique platforms that streamline the operations. The Icertis Contract Intelligence (ICI) platform is being publicized for the same and has been preferred by Sanofi to accelerate drug trials whilst facilitating compliance in a tightly regulated environment. Such platforms are revolutionizing procurement contracting processes that result in improving supplier relations.
The pharmaceutical contract sales outsourcing (CSO) market is expected to reach US$ 14.7 Bn by 2031. The growing expectations of pharmaceutical manufacturers from contract sales companies involve saving time and effort on recruitment, building the sales team quickly, and reducing the sales team overhead. Thus, to achieve this, sales companies are attracting qualified medical sales representatives, networking with different contacts, and using a part-time contract sales team.
There is a need for reducing business risk among pharmaceutical manufacturers. Companies in the pharmaceutical contract sales outsourcing (CSO) market are gaining awareness and establishing part-time contract sales teams that eliminate the need to invest in and maintain a permanent infrastructure. Pharma companies are willing to see the CSO’s experience in the medical sales industry before agreeing to the contract.
Pharmaceutical companies are leveraging outsourced sales teams. Apart from time and money savings of using outsourced sales services, pharmaceutical manufacturers are turning to outsource their sales processes, simply to minimize their management burden. Such trends are translating into revenue opportunities for stakeholders in the pharmaceutical contract sales outsourcing (CSO) market. Advantages of leveraging outsourced sales teams such as instant access to a large talent pool, cost savings on staff management, and flexibility in operations are grabbing the attention of pharma companies.
Outsourced sales services provide access to exclusive sales and customer relationship management tools. Companies in the pharmaceutical contract sales outsourcing (CSO) market are providing fresh strategic insight to help pharma companies gain a competitive edge over other manufacturers. Onboarding fresh outside talent to manage sales processes can provide a pharma company new insights on meeting new sales goals.
Analysts’ Viewpoint
Stakeholders in the pharmaceutical contract sales outsourcing (CSO) market are working with pharma customers who are in need of products more urgently than others during the COVID-19 outbreak. The growing number of biologics in development is driving the demand for high-tech development and manufacturing solutions. However, most biologics are complex and cannot be fully distinguished by science alone. Hence, companies are increasing their R&D to develop contract intelligence platforms, which help to accelerate drug trials in highly regulated promotional programs. These platforms help to reduce risk by improving visibility into compliance requirements and other obligations. The state-of-the-art technology can be a key differentiator in medical sales negotiations.
Pharmaceutical Contract Sales Outsourcing (CSO) Market – Segmentation
| Service |
|
| Therapeutic Area |
|
| Region |
|
Pharmaceutical contract sales outsourcing (CSO) market is expected to reach US$ 14.7 Bn by 2031
Pharmaceutical contract sales outsourcing [CSO] market is projected to expand at a favorable CAGR of ~7% from 2021 to 2031
Pharmaceutical contract sales outsourcing [CSO] market is driven by increase in R&D and other operating costs in pharmaceutical industries induces medium and large pharmaceutical companies to outsource their sales operations
North America is expected to account for a significant share of the global pharmaceutical contract sales outsourcing (CSO) market during the forecast period
The personal promotion segment dominated the global pharmaceutical contract sales outsourcing [CSO] market
Key players operating in the global pharmaceutical contract sales outsourcing (CSO) market include Ashfield (UDG Healthcare plc), inVentiv Health, Inc. (Syneos Health), IQVIA, Granard Pharmaceutical Sales & Marketing, Vanguard Pharma, Inc., GTS Solution, EVERSANA
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market
4. Market Overview
4.1. Introduction
4.1.1. Market Introduction
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Healthcare Industry Overview
5.2. Impact of Sunshine Act on Contract Sales
5.3. COVID-19 Pandemics Impact on Industry (Value Chain and Short /Mid / Long Term Impact)
6. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Service
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Service, 2017–2031
6.3.1. Personal Promotion
6.3.1.1. Promotional Sales Team
6.3.1.1.1. Dedicated Sales Team
6.3.1.1.2. Syndicated Sales Team
6.3.1.2. Key Account Management
6.3.1.3. Vacancy Management
6.3.2. Non-personal Promotion
6.3.2.1. Tele-detailing
6.3.2.2. Interactive E-detailing
6.3.2.3. Customer Service
6.3.2.4. Medical Science Liaisons
6.3.2.5. Patient Engagement Services
6.3.2.6. Others
6.3.3. Other Services
6.4. Market Attractiveness Analysis, by Service
7. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Therapeutic Area
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Therapeutic Area, 2017–2031
7.3.1. Cardiovascular Disorders
7.3.2. Oncology
7.3.3. Metabolic Disorders
7.3.4. Neurology
7.3.5. Orthopedic Diseases
7.3.6. Infectious Diseases
7.3.7. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area
8. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Region
9. North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Service, 2017–2031
9.2.1. Personal Promotion
9.2.1.1. Promotional Sales Team
9.2.1.1.1. Dedicated Sales Team
9.2.1.1.2. Syndicated Sales Team
9.2.1.2. Key Account Management
9.2.1.3. Vacancy Management
9.2.2. Non-personal Promotion
9.2.2.1. Tele-detailing
9.2.2.2. Interactive E-detailing
9.2.2.3. Customer Service
9.2.2.4. Medical Science Liaisons
9.2.2.5. Patient Engagement Services
9.2.2.6. Others
9.2.3. Other Services
9.3. Market Value Forecast, by Therapeutic Area, 2017–2031
9.3.1. Cardiovascular Disorders
9.3.2. Oncology
9.3.3. Metabolic Disorders
9.3.4. Neurology
9.3.5. Orthopedic Diseases
9.3.6. Infectious Diseases
9.3.7. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Service
9.5.2. By Therapeutic Area
9.5.3. By Country
10. Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Service, 2017–2031
10.2.1. Personal Promotion
10.2.1.1. Promotional Sales Team
10.2.1.1.1. Dedicated Sales Team
10.2.1.1.2. Syndicated Sales Team
10.2.1.2. Key Account Management
10.2.1.3. Vacancy Management
10.2.2. Non-personal Promotion
10.2.2.1. Tele-detailing
10.2.2.2. Interactive E-detailing
10.2.2.3. Customer Service
10.2.2.4. Medical Science Liaisons
10.2.2.5. Patient Engagement Services
10.2.2.6. Others
10.2.3. Other Services
10.3. Market Value Forecast, by Therapeutic Area, 2017–2031
10.3.1. Cardiovascular Disorders
10.3.2. Oncology
10.3.3. Metabolic Disorders
10.3.4. Neurology
10.3.5. Orthopedic Diseases
10.3.6. Infectious Diseases
10.3.7. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Service
10.5.2. By Therapeutic Area
10.5.3. By Country/Sub-region
11. Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Service, 2017–2031
11.2.1. Personal Promotion
11.2.1.1. Promotional Sales Team
11.2.1.1.1. Dedicated Sales Team
11.2.1.1.2. Syndicated Sales Team
11.2.1.2. Key Account Management
11.2.1.3. Vacancy Management
11.2.2. Non-personal Promotion
11.2.2.1. Tele-detailing
11.2.2.2. Interactive E-detailing
11.2.2.3. Customer Service
11.2.2.4. Medical Science Liaisons
11.2.2.5. Patient Engagement Services
11.2.2.6. Others
11.2.3. Other Services
11.3. Market Value Forecast, by Therapeutic Area, 2017–2031
11.3.1. Cardiovascular Disorders
11.3.2. Oncology
11.3.3. Metabolic Disorders
11.3.4. Neurology
11.3.5. Orthopedic Diseases
11.3.6. Infectious Diseases
11.3.7. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Service
11.5.2. By Therapeutic Area
11.5.3. By Country/Sub-region
12. Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Service, 2017–2031
12.2.1. Personal Promotion
12.2.1.1. Promotional Sales Team
12.2.1.1.1. Dedicated Sales Team
12.2.1.1.2. Syndicated Sales Team
12.2.1.2. Key Account Management
12.2.1.3. Vacancy Management
12.2.2. Non-personal Promotion
12.2.2.1. Tele-detailing
12.2.2.2. Interactive E-detailing
12.2.2.3. Customer Service
12.2.2.4. Medical Science Liaisons
12.2.2.5. Patient Engagement Services
12.2.2.6. Others
12.2.3. Other Services
12.3. Market Value Forecast, by Therapeutic Area, 2017–2031
12.3.1. Cardiovascular Disorders
12.3.2. Oncology
12.3.3. Metabolic Disorders
12.3.4. Neurology
12.3.5. Orthopedic Diseases
12.3.6. Infectious Diseases
12.3.7. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Service
12.5.2. By Therapeutic Area
12.5.3. By Country/Sub-region
13. Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Service, 2017–2031
13.2.1. Personal Promotion
13.2.1.1. Promotional Sales Team
13.2.1.1.1. Dedicated Sales Team
13.2.1.1.2. Syndicated Sales Team
13.2.1.2. Key Account Management
13.2.1.3. Vacancy Management
13.2.2. Non-personal Promotion
13.2.2.1. Tele-detailing
13.2.2.2. Interactive E-detailing
13.2.2.3. Customer Service
13.2.2.4. Medical Science Liaisons
13.2.2.5. Patient Engagement Services
13.2.2.6. Others
13.2.3. Other Services
13.3. Market Value Forecast, by Therapeutic Area, 2017–2031
13.3.1. Cardiovascular Disorders
13.3.2. Oncology
13.3.3. Metabolic Disorders
13.3.4. Neurology
13.3.5. Orthopedic Diseases
13.3.6. Infectious Diseases
13.3.7. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Service
13.5.2. By Therapeutic Area
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by Tier and Size of companies)
14.2. Market Share Analysis/Ranking, by Company, 2020
14.3. Company Profiles
14.3.1. Ashfield (UDG Healthcare plc)
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Growth Strategies
14.3.1.3. SWOT Analysis
14.3.2. inVentiv Health, Inc. (Syneos Health)
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Growth Strategies
14.3.2.3. SWOT Analysis
14.3.3. IQVIA
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Growth Strategies
14.3.3.3. SWOT Analysis
14.3.4. Granard Pharmaceutical Sales & Marketing
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Growth Strategies
14.3.4.3. SWOT Analysis
14.3.5. Vanguard Pharma, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Growth Strategies
14.3.5.3. SWOT Analysis
14.3.6. GTS Solution
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Growth Strategies
14.3.6.3. SWOT Analysis
14.3.7. EVERSANA
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Growth Strategies
14.3.7.3. SWOT Analysis
14.3.8. MaBiCo
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Growth Strategies
14.3.8.3. SWOT Analysis
14.3.9. QFR Solutions
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Growth Strategies
14.3.9.3. SWOT Analysis
14.3.10. Pharmaforce Ireland Ltd.
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Growth Strategies
14.3.10.3. SWOT Analysis
14.3.11. Sales Focus, Inc.
14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.11.2. Growth Strategies
14.3.11.3. SWOT Analysis
14.3.12. Amplity Health
14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.12.2. Growth Strategies
14.3.12.3. SWOT Analysis
List of Tables
Table 01: Healthcare Industry Overview (2019 or latest available)
Table 02: List of Pharmaceutical CSO companies by Region
Table 03: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 04: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 05: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 06: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 07: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 08: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 09: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 10: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 11: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 12: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 13: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 14: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 15: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 17: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 18: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 19: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 20: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 21: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 23: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 24: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 25: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 26: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 27: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 28: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 29: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 30: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 31: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 32: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
Table 33: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 34: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Service, 2017–2031
Table 35: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Personal Promotion, 2017–2031
Table 36: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Promotional Sales Team, 2017–2031
Table 37: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Non-personal Promotion, 2017–2031
Table 38: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2031
List of Figures
Figure 01: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Service, 2020
Figure 03: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Therapeutic Area, 2020
Figure 04: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share, by Region, 2020
Figure 05: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2020 and 2031
Figure 06: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2021–2031
Figure 07: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Personal Promotion, 2017–2031
Figure 08: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Non-personal Promotion, 2017–2031
Figure 09: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Others, 2017–2031
Figure 10: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2020 and 2031
Figure 11: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2021–2031
Figure 12: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Cardiovascular Disorders, 2017–2031
Figure 13: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Oncology, 2017–2031
Figure 14: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Metabolic Disorders, 2017–2031
Figure 15: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Neurology, 2017–2031
Figure 16: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Orthopedic Diseases, 2017–2031
Figure 17: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), Infectious Diseases, 2017–2031
Figure 18: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Revenue (US$ Mn), by Others, 2017–2031
Figure 19: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Region, 2020 and 2031
Figure 20: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Region, 2021–2031
Figure 21: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 22: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Country, 2020 and 2031
Figure 23: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Country, 2021–2031
Figure 24: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2020 and 2031
Figure 25: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2021–2031
Figure 26: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2020 and 2031
Figure 27: North America Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2021–2031
Figure 28: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 29: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 30: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 31: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2020 and 2031
Figure 32: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2021–2031
Figure 33: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2020 and 2031
Figure 34: Europe Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2021–2031
Figure 35: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 36: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 37: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 38: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2020 and 2031
Figure 39: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2021–2031
Figure 40: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2020 and 2031
Figure 41: Asia Pacific Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2021–2031
Figure 42: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 43: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 44: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 45: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2020 and 2031
Figure 46: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2021–2031
Figure 47: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2020 and 2031
Figure 48: Latin America Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2021–2031
Figure 49: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value (US$ Mn) Forecast, 2017–2031
Figure 50: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 51: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 52: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Service, 2020 and 2031
Figure 53: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Service, 2021–2031
Figure 54: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Value Share Analysis, by Therapeutic Area, 2020 and 2031
Figure 55: Middle East & Africa Pharmaceutical Contract Sales Outsourcing (CSO) Market Attractiveness Analysis, by Therapeutic Area, 2021–2031
Figure 56: Global Pharmaceutical Contract Sales Outsourcing (CSO) Market: Company Share Analysis, 2020
Figure 57: UDG Healthcare plc - Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 58: UDG Healthcare plc - Breakdown of Net Sales (%), by Region/Country, 2020
Figure 59: UDG Healthcare plc - Breakdown of Net Sales (%), by Business Segment, 2020
Figure 60: Ashfield - Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 61: Syneos Health - Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2019
Figure 62: Syneos Health - Breakdown of Net Sales (%), by Region/Country, 2019
Figure 63: Syneos Health - Breakdown of Net Sales (%), by Business Segment, 2019
Figure 64: IQVIA Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Figure 65: IQVIA Breakdown of Net Sales (%), by Region/Country, 2020
Figure 66: IQVIA Breakdown of Net Sales (%), by Business Segment, 2020
Figure 67: IQVIA Contract Sales & Medical Solutions Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2020
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Pharmaceutical Contract Sales Outsourcing [CSO] Market Trends, 2021-2031
